MY004 / Createrna - LARVOL DELTA

Therapeutic Potential of MY004, an IRAK4 Inhibitor, in Psoriasis: Preclinical Activity and Molecular Mechanism (ISDS 2025) - " To evaluate the therapeutic potential of MY004, a selective IRAK4 inhibitor, we used two well-characterized murine psoriasis models: IL-23–induced and imiquimod (IMQ)–induced skin inflammation...Repeat administration of MY004 at high-dose was associated with durable suppression of many disease-marker genes; exploratory comparisons suggested potential durability benefits when evaluated alongside the TYK2 inhibitor BMS-986165. Preclinical data support IRAK4 as a central pathogenic driver of psoriasis and demonstrate that MY004 effectively attenuates psoriatic inflammation through targeted disruption of TLR/IL-1R–dependent signaling. Compared to benchmark therapy, MY004 shows potential for enhanced durability of response, underscoring its promise as a novel therapeutic option in psoriasis."

IO biomarker • Preclinical • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • IFNG • IL17A • IL1R1 • IL22 • IL23A • IRAK4 • MYD88 • TNFA • TRAF6 • TYK2

Pharmacokinetic Study of MY004567 Tablets in Patients with Moderate to Severe Active Rheumatoid Arthritis (ChiCTR) - P1 | N=10 | Recruiting | Sponsor: The First Hospital of Jilin University; The First Hospital of Jilin University

New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP